Advertisement
Original article| Volume 7, ISSUE 4, P416-421, August 1993

Download started.

Ok

Calculating the protamine-heparin reversal ratio: A pilot study investigating a new method

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      There is no consensus as to the dosage of protamine required to reverse a given dose of heparin. The amounts advised vary widely. The hypothesis was investigated that doses of protamine smaller than those usually recommended could be used following cardiac surgery to successfully reverse heparin activity as measured by the activated coagulation time (ACT). A group of 18 patients scheduled for cardiopulmonary bypass (CPB) were investigated with their informed consent. A baseline ACT was measured before anticoagulation with heparin. At the end of CPB, an initial neutralizing dose (IND) of protamine (2 mg/kg) was administered. The ACT was measured after 5 minutes and a further dose of protamine (2 mg/kg) was then administered to make up the full dose. The heparin activity (HA) before and after the IND of protamine reversal was calculated according to the method described by Bull.1 The IND of protamine (2 mg/kg) was expressed as a ratio of the change in HA (the latter also expressed as mg/ kg). The average ± standard deviation (SD) preoperative ACT was 155 ± 21 seconds with a range of 130 to 199 seconds. Following heparin administration the ACT increased to 701 ± 152 seconds. After the IND of protamine, the average ACT of 160 ± 31 (range, 121 to 250) was not statistically (NS) significantly different from the starting value. A further dose of 2 mg/kg of protamine (“full-dose”) decreased (NS) the ACT only minimally to an average of 151 ± 18 (range, 128 to 206) seconds. The HA before and after the IND of protamine reversal was 3.81 ± 1.11 mg/ kg (range, 2.34 to 6.19) and 0.06 ± 0.38 mg/kg (range, -0.37 to +1.16). This change in HA was caused by an average dose of 2.01 ± 0.09 mg/kg of protamine (ie, 1 mg of heparin activity was reversed by 0.6 ± 0.14 mg of protamine). It is concluded that the proper dose of protamine required to reverse heparin is less than usually recommended and can be calculated using this new ratio.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiothoracic and Vascular Anesthesia
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bull B.S.
        • Huse W.M.
        • Brauer F.S.
        • et al.
        Heparin therapy during extracorporeal circulation (11). The use of a dose-response curve to individualize heparin and protamine dosage.
        J Thorac Cardiovasc Surg. 1975; 69: 685-689
        • Horrow J.C.
        Protamine: A review of its toxicity.
        Anesth Analg. 1985; 64: 348-361
        • Dutton D.A.
        • Hothersall A.P.
        • MacLaren A.D.
        • et al.
        Protamine titration after cardiopulmonary bypass.
        Anaesthesia. 1983; 38: 264-268
        • Kresowik T.F.
        • Wakefield T.W.
        • Fessler II, R.D.
        • et al.
        Anticoagulant effects of protamine sulfate in a canine model.
        J Surg Res. 1988; 45: 8-14
        • Morel D.R.
        • Zapol W.M.
        • Thomas S.J.
        • et al.
        C5a and thromboxane generation associated with pulmonary vaso and bronchoconstriction during protamine reversal of heparin.
        Anesthesiology. 1987; 66: 597-604
        • Colman R.W.
        Humoral mediators of catastrophic reactions associated with protamine neutralization.
        Anesthesiology. 1987; 66: 595-596
        • Tan F.
        • Jackman H.
        • Skidgel R.A.
        • et al.
        Protamine inhibits plasma carboxypeptidase N, the inactivator of anaphylatoxins and kinins.
        Anesthesiology. 1989; 70: 267-275
        • Guffin A.V.
        • Dunbar R.W.
        • Kaplan J.A.
        • et al.
        Successful use of a reduced dose of protamine after cardiopulmonary bypass.
        Anesth Analg. 1976; 55: 110-113
        • Perkins H.A.
        • Osborn J.J.
        • Hurt R.
        • et al.
        Neutralization of heparin in vivo with protamine; a simple method of estimating the required dose.
        J Lab Clin Med. 1956; 48: 223-226
        • Berger R.L.
        • Ramaswamy K.
        • Ryan T.J.
        Reduced protamine dosage for heparin neutralization in open-heart operations.
        Circulation. 1968; 37: II-154-II-157
        • Culliford A.T.
        • Gitel S.N.
        • Starr N.
        • et al.
        Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass.
        Ann Surg. 1980; 193: 105-111
        • Ellison N.
        • Ominsky A.J.
        • Wollman H.
        Is protamine a clinically important anticoagulant? A negative answer.
        Anesthesiology. 1971; 35: 621-629
        • Raby C.
        • Seville M.
        Determinatio precise de l'heparinemie reelle on momeny ou simpose sa neutralisation per le polybrene ou le sulfate de protamine.
        Hemostase. 1962; 2: 325